Intellia Therapeutics, Inc.
NASDAQ:NTLA · NASDAQ Global Market
+$0.02 today
Vol 7.50M · Avg 6.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.5%
avg -34.5%
ROIC
-57.7%
avg -30.9%
ROA
-49.0%
avg -27.2%
Analysis
ROA is currently the strongest return metric at -49.0% versus its period average of -27.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Erik J. Sontheimer | Founder and Member of Scientific Advisor Board | $1.38M | — | — | — | — |
Luciano Marraffini | Founder and Member of Scientific Advisor Board | $1.38M | — | — | — | — |
Derrick J. Rossi | Founder and Member of Scientific Advisor Board | $1.38M | — | — | — | — |
Rodolphe Barrangou | Founder and Member of Scientific Advisor Board | $1.38M | — | — | — | — |
Jennifer A. Doudna | Founder and Member of Scientific Advisor Board | $1.38M | — | 62 | — | — |
John Leonard | President, Chief Executive Officer & Director | $1.26M | — | 69 | $1.17M | 1.04% |
Edward J. Dulac | Executive Vice President, Chief Financial Officer and Treasurer | $853,712.00 | — | 50 | $160,963.00 | 0.14% |
David Lebwohl | Executive Vice President & Chief Medical Officer | $781,359.00 | — | 71 | $14,204.00 | 0.01% |
James E. Basta | Executive Vice President, General Counsel & Corporate Secretary | $732,367.00 | — | 60 | $156,794.00 | 0.14% |
Birgit Schultes | Executive VP & Chief Scientific Officer | $708,860.00 | — | 63 | $137,733.00 | 0.12% |
Michael Dube | VP & Chief Accounting Officer | $478,489.00 | — | 48 | $69,527.00 | 0.06% |
Eliana Clark | Executive VP & Chief Technical Officer | — | — | 68 | $93,864.00 | 0.08% |
Jason Fredette | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Rachel E. Haurwitz | Co-Founder | — | — | 40 | $5.59M | 4.99% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.41M
Sells
19
$1.84M
Net Sentiment
+$570,241.77
Net buying
Most Active
LEONARD JOHN M
4 transactions
1–10 of 21
Analysis
Insiders reported 2 buys worth $2.41M and 19 sells worth $1.84M over the last 12 months. That adds up to net buying of $570,241.77. LEONARD JOHN M was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +71.4% | +45.4% (12yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +71.4% over three years. Forward estimates point to Revenue at +45.4% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.34B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.91B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.87B
Immunome, Inc.
NASDAQ:IMNM
$1.73B
Zymeworks Inc.
NASDAQ:ZYME
$1.67B
Biohaven Ltd.
NYSE:BHVN
$1.42B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.16B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$860.25M
Upstream Bio, Inc.
NASDAQ:UPB
$339.31M
Who manages NTLA?
Intellia Therapeutics, Inc. (NTLA) lists 14 active executives. The top listed executive is Michael Dube, VP & Chief Accounting Officer.
Are NTLA insiders buying or selling?
Recent insider activity shows net buying of $45.74M.
Explore More
Continue the stock analysis
Jump to another research area for this company.